Evidence map›Paper›PMID 37607769›Full record

ArticleJournal for immunotherapy of cancer2023

Id-neoantigen vaccine induces therapeutic CD8

Marita Westhrin, Jana Blazevski, Ana Textor, Pegah Abdollahi, Ramakrishna Prabhu Gopalakrishnan, Linda Thuy Ngo, Peter Olaf Hofgaard, Julia Heinzelbecker, Sonja Bobic, Even Fossum and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Marita WesthrinDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Jana Blazevski *Department of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ana Textor *Department of Immunology, Oslo University Hospital, Oslo, Norway.
Pegah AbdollahiDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Ramakrishna Prabhu GopalakrishnanDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Linda Thuy NgoDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Peter Olaf HofgaardDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Julia HeinzelbeckerDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Sonja BobicDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Even FossumDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Heidi Cecilie Larsen SpångDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ranveig BraathenDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway ranveig.braathen@medisin.uio.no.ORCID 0000-0003-0451-5936
Bjarne BogenDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) cancers originate from plasma cells that have passed through the germinal center reaction where somatic hypermutation of Ig V regions takes place. Myeloma protein V regions often express many mutations and are thus a rich source of neoantigens (traditionally called idiotopes (Id)). Therefore, these are highly tumor-specific and excellent targets for immunotherapy.

methodsWe have developed a DNA Id vaccine which as translated protein targets conventional dendritic cells (cDC) for CCL3-mediated delivery of myeloma protein V regions in a single-chain fragment variable (scFv) format. Vaccine efficacy was studied in the mouse MM model, mineral oil-induced plasmacytoma 315.BM.

resultsThe Id vaccine protected mice against a challenge with MM cells. Moreover, the vaccine had a therapeutic effect. However, in some of the vaccinated mice, MM cells not producing H chains escaped rejection, resulting in free light chain (FLC) MM. Depletion of CD8

conclusionsV

Indexed as

Multiple MyelomaVaccines, DNAAnimalsCD8-Positive T-LymphocytesDendritic CellsImmunotherapyMiceVaccines, DNACD8-Positive T-LymphocytesCytotoxicity, ImmunologicImmunity, CellularImmunogenicity, VaccineImmunotherapy

Identifiers

PMID37607769
PMCPMC10445383
OpenAlexW4386082903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.